Guillain-Barré Syndrome (GBS)
Evidence-Based Overview for Clinicians and Families Overview:
Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening acute immune-mediated polyneuropathy in which the body’s immune system mistakenly attacks peripheral nerves. It is one of the most common causes of acute flaccid paralysis worldwide and typically presents with rapidly progressive, symmetrical weakness.
GBS is considered a neurological emergency due to its potential to affect respiratory muscles and autonomic function.
Etiology and Pathophysiology:
Post-Infectious Trigger
In most cases, GBS occurs following an infection, commonly affecting the respiratory or gastrointestinal systems. The most frequently associated pathogen is Campylobacter jejuni, although viral infections such as cytomegalovirus, Epstein-Barr virus, and influenza have also been implicated.
Molecular Mimicry Mechanism:
The underlying mechanism is known as molecular mimicry, where antigens on infectious agents resemble components of peripheral nerves, particularly gangliosides on Schwann cells. This leads to an autoimmune response in which antibodies mistakenly target peripheral nerve myelin or axons, resulting in impaired nerve conduction and muscle weakness (Willison et al., 2016).
Clinical Presentation:
Symptoms typically develop 1–3 weeks after infection and progress rapidly, often reaching peak severity within 4 weeks.
Early Signs:
• Paresthesia (tingling in hands and feet)
• Ascending symmetrical weakness (starting in lower limbs)
• Reduced or absent deep tendon reflexes
• Gait instability
• Neuropathic pain
Progressive and Severe Features:
• Facial weakness and bulbar dysfunction (difficulty swallowing, speaking)
• Diplopia (double vision)
• Respiratory muscle weakness → respiratory failure risk
• Autonomic dysfunction (heart rate and blood pressure instability)
• Bladder or bowel dysfunction
Diagnosis and Clinical Evaluation:
Diagnosis is primarily clinical and supported by investigations:
• Clinical examination: Rapid, symmetrical ascending weakness with areflexia
• Lumbar puncture: Albumin cytologic dissociation (elevated protein with normal WBC count)
• Nerve conduction studies (NCS/EMG): Demyelination or axonal neuropathy patterns
• Brighton criteria: Used to classify diagnostic certainty
• MRI: Excludes spinal cord pathology and may show nerve root enhancement
• Pulmonary function tests: Monitor respiratory involvement and ventilation need
Medical Management:
GBS requires urgent hospital admission and multidisciplinary care.
Disease-Modifying Treatment
• Intravenous immunoglobulin (IVIG)
• Plasmapheresis (plasma exchange)
Both treatments are equally effective in reducing disease severity and improving recovery outcomes when initiated early.
Supportive Care:
• Respiratory monitoring and ventilatory support if needed
• Cardiac and autonomic stability monitoring
• Pain management
• Prevention of complications (pressure sores, thrombosis)
Early rehabilitation input is essential even during the acute phase.
Physiotherapy Management in GBS
Physiotherapy plays a critical role in preventing complications and restoring function and must be carefully adapted to the disease stage:
1. Early Stage (Severe Weakness)
• Passive range of motion (PROM)
• Positioning to prevent contractures
• Chest physiotherapy if indicated
• Pressure area care support
2. Recovery Phase
• Active-assisted exercises
• Gradual activation of antigravity muscles
• Neuromuscular re-education
3. Strengthening Phase
• Low-intensity, graded strengthening
• Avoidance of overwork weakness and fatigue
• Functional task training
4. Gait and Functional Training
• Balance retraining
• Assistive device training
• Progressive walking re-education
5. Pain and Fatigue Management
• Energy conservation strategies
• Activity pacing
• Education for patient and family
Role of Physiotherapist:
• Prevent secondary complications (contractures, deconditioning)
• Monitor fatigue and avoid overtraining
• Facilitate safe functional recovery
• Support psychological adaptation
• Educate caregivers on safe handling and progression
Recovery and Prognosis
Recovery varies depending on severity, but:
• Most patients begin improvement within weeks after disease plateau
• Full recovery may take months to over one year
• Fatigue is common even after motor recovery
Early rehabilitation significantly improves long-term outcomes (Shahrizaila & Yuki, 2021).
Family Guidance:
• Recovery is gradual; patience is essential
• Encourage participation without forcing fatigue
• Ensure safe home environment
• Maintain continuous communication with the rehabilitation team
• Provide emotional and psychological support
References :
Shahrizaila, N., & Yuki, N. (2021). Guillain-Barré syndrome. The Lancet, 397(10280), 1214–1228. https://doi.org/10.1016/S0140-6736(21)00517-4
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. The Lancet, 388(10045), 717–727. https://doi.org/10.1016/S0140-6736(16)00339-1
Van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014). Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment, and prognosis. Nature Reviews Neurology, 10(8), 469–482. https://doi.org/10.1038/nrneurol.2014.121
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., et al. (2019). Diagnosis and management of Guillain-Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671–683. https://doi.org/10.1038/s41582-019-0250-9